Thalys(SH:603716) news flash·2025-07-14 08:56Core Viewpoint - The company, Sely Medical (603716.SH), anticipates a net loss attributable to shareholders of between -55 million to -66 million yuan for the first half of 2025, indicating an increase in losses compared to the same period last year [1] Group 1: Financial Performance - The expected net profit loss for the first half of 2025 is projected to be between -55 million to -66 million yuan, which represents a worsening of losses compared to the previous year [1] - The company has undergone strategic transfers of certain subsidiaries, which has had a short-term negative impact on overall revenue scale and gross profit levels [1] Group 2: Strategic Transition - The company is currently in a strategic transition phase, focusing on upgrading from traditional medical supply chain services to medical intelligence [1] - Industry policies have influenced the company's operations, leading to extended collection periods for accounts receivable from some clients [1] Group 3: Revenue and Profitability Challenges - The company has experienced a decline in operating revenue and gross profit due to the lack of renewal arrangements for certain businesses after their expiration [1]